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Desmoplastic melanoma (DM) is a variant of melanoma characterized by the presence of amelanotic fusiform
melanocytes dispersed in a prominent collagenous stroma. DM behaves differently from conventional non-des-
moplastic melanoma (NDM). It has a higher tendency for local recurrence and is less likely to metastasize to
regional lymph nodes. In this study, we explored the possibility of distinguishing DM from NDM by gene expression
proﬁling. RNA samples from ten primary cutaneous melanomas of similar depth of invasion were analyzed using
the Affymetrix U133A oligonucleotide platform. Four tumors were DM, ﬁve were ND, and one tumor showed com-
bined features of desmoplastic and conventional. Hierarchical cluster analysis clearly separated DM from NDM. The
expression of a number of melanocyte differentiation genes was decreased in DM compared with NDM, which
corresponded to immunohistochemical results. Various genes were upregulated in DM, including neurotrophic
factors and genes involved in extracellular matrix production. A novel ﬁnding was the high expression of clusterin
in DM, which was conﬁrmed by immunohistochemical studies. Our results from gene expression proﬁling validate
the distinction of DM from NDM. They also provide the opportunity to learn more about the biology of DM which had
previously not yet been associated with this variant of melanoma.
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Invasive melanoma may express a variety of histologic ap-
pearances, including the common picture of densely cellu-
lar pigmented or non-pigmented epithelioid cell tumor and
the uncommon ‘‘sarcomatoid’’ spindle cell phenotype. Des-
moplastic melanoma (DM) is a histologic variant of spindle
cell melanoma characterized by the dispersion of fusiform
tumor cells in a prominent collagenous stroma (Conley et al,
1971; Egbert et al, 1988; Jain and Allen, 1989; Smithers
et al, 1990; Baer et al, 1995; Carlson et al, 1995; Skelton
et al, 1995). It typically affects the head and neck region of
elderly individuals with chronic sun damage. DM differs in
its clinical behavior from conventional non-desmoplastic
melanoma (NDM) by a higher incidence of local recurrence
and less frequent involvement of regional lymph nodes
(Skelton et al, 1995; Quinn et al, 1998; Jaroswewski et al,
2001; Thelmo et al, 2001; Gyorki et al, 2003).
In this study, we explored the use of gene expression
profiling for the distinction of DM from NDM. If the profile of
expressed genes permitted classification of DM as separate
from NDM, this would establish a genomic basis for the
observed clinical and pathologic studies, which have led to
the proposition of DM as a distinct melanoma subtype. The
pattern of genes might also yield new insights into the bi-
ology of DM and possibly prompt further studies that may
eventually lead to the discovery of novel diagnostically use-
ful reagents.
Results
Histologic ﬁndings The histologic findings of the tumors
used for this analysis are summarized in Table I. The tumors
ranged in thickness from 5.1 to 28 mm. All but one tumor
extended into the subcutis (Clark level V). Four melanomas
were amelanotic desmoplastic spindle cell tumors. Five
were ‘‘conventional’’ NDM. One tumor was a melanoma
with combined desmoplastic and non-desmoplastic fea-
tures (CDM). One of the conventional melanomas arose in a
congenital nevus. All other tumors arose de novo without an
associated nevus component. All DM were anatomically
located in the head and neck region. Four NDM were from
the trunk, one was from the foot. The one melanoma with
combined desmoplastic and non-desmoplastic features
(CDM) was also from the foot.
Typical examples of invasive DM (case 1, Table I) and
NDM (case 6, Table I) are illustrated in Fig 1. DM were
characterized by the presence of atypical amelanotic spin-
dle cells dispersed in a fibrous stroma. In NDM, epithelioid
melanocytes were closely apposed, forming nodules of
dense cellular aggregates without any or only minimal int-
ratumoral fibrosis.
Abbreviations: DM, desmoplastic melanoma; gp100, glycoprotein
100; H&E, hematoxylin and eosin; NDM, non-desmoplastic me-
lanoma
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Expression proﬁling Hierarchical clustering clearly distin-
guished DM from NDM (Fig 2). The one tumor with com-
bined features showed a mixed profile of genes, with an
overall pattern, however, slightly closer to DM than NDM. A
total of 629 genes were found to differ at least 2-fold be-
tween DM and NDM (p-value¼0.05).
One group of genes that showed a great difference in
levels of expression between DM and NDM were those re-
lated to melanin pigment synthesis (melanocyte differenti-
ation antigens; Table II). The level of expression of five
members of this group, for example, was 38-fold or more
decreased in DM, including the gene involved in ocular al-
binism 1 (G protein-coupled receptor 143), melan-A/Mart-1,
dopachrome tautomerase (DTC), which is also known as
tyrosinase-related protein (TRP)-2, glycoprotein (gp)100
(silver locus), and tyrosinase.
DM and NDM also differed in a variety of other genes, i.e.
genes not related to melanin pigment synthesis. Examples
of such genes, whose expression was at least 10-fold dif-
ferent between DM and NDM, are listed in Table III.
Genes encoding for neurotrophic factors (e.g., nerve growth
factor receptor (NGFR), glial cell line-derived neurotrophic
factor, pleiotrophin) and proteins involved in the production
and homeostasis of fibrous matrix (e.g., tissue factor path-
way inhibitor, tissue metalloproteinase inhibitor, serine pro-
teinase inhibitor) were more prominently expressed in DM
Figure 1
Histologic appearance of desmoplastic (DM)
and conventional epithelioid, i.e. non-desmo-
plastic melanoma (NDM). In DM (A), atypical
fusiform melanocytes are dispersed in a colla-
genous stroma. In NDM (B), epithelioid melano-
cytes are arranged in nested cellular aggregates
with little or no intratumoral fibrosis.
Table I. Histologic features of the tumor samples
Melanoma 1 2 3 4 5 6 7 8 9 10
Type DM DM DM DM CDM NDM NDM NDM NDM NDM
Thickness (mm) 6.5 14 6 26 15 19 21 5.1 5.9 28
Level V V V V V V V IV V V
DM, desmoplastic melanoma; NDM, non-desmoplastic melanoma; CDM, combined desmoplastic melanoma.
Figure2
Hierarchical clustering of 629 genes separates desmoplastic me-
lanoma (DM) from conventional non-desmoplastic melanoma
(NDM). Cases 1–5 represent melanomas with desmoplasia (1–4 are
typical DMs, case 5 is a melanoma with only partial desmoplasia tu-
mors, 6–10 are melanomas without demoplasia).
DISTINCTION OF DM FROM NDM 413124 : 2 FEBRUARY 2005
than NDM. Among the genes with increased expression in
DM compared with NDM, the greatest difference was seen
for clusterin (31-fold increase in DM; Table III).
Validation of microarray results by immunohistochem-
istry Immunohistochemical studies were performed for S-
100 protein and a subset of melanocyte differentiation an-
tigens (melan-A/Mart-1, tyrosinase, gp100, microphthalmia
transcription factor) for comparison with gene expression
data. A tissue array with triplicate samples from each tumor
that had been analyzed by gene expression profiling was
used. As illustrated in Table IV, all tumors were positive for
S-100 protein. None of the DM was immunopositive for
gp100 (HMB-45), melan-A (A103), tyrosinase (T311), or mi-
crophthalmia transcription factor (D5), whereas all NDM
were at least focally positive for each of these markers. The
CDM showed focal staining with A103, T311, and D5, but
was negative with HMB-45.
Immunohistochemistry was also performed for clusterin
using sections from the same tissue array. This protein was
chosen for validation of the array data, because its expres-
sion showed the strongest association with DM and a re-
agent suitable for analysis on archival material was
available. As shown in Fig 3 and Table V, immunostaining
for clusterin was expressed in all four DM. Only one case of
conventional melanoma and the case of CDM had tumors
cells that were weakly positive for clusterin. The remaining
four NDM were completely negative for clusterin.
Discussion
DM is a fibrosing variant of melanoma. In the first report on
DM by Conley in 1971, DM was defined as ‘‘a very unusual
variant of spindle cell melanoma which produces or elicits
the production of abundant collagen’’ (Conley et al, 1971).
Table II. Comparison of melanocyte differentiation antigens
between DM and NDM
Gene name UniGene Gene ID
DM
versus
NDM (fold
change)
GPR143: G protein-coupled
receptor 143a
Hs.74124 4935 85
MLANA: Melan-A Hs.154026 2315 50
DCT: dopachrome
tautomeraseb
Hs.301865 1638 46
SILV: silver homolog
(glycoprotein 100)
Hs.95972 6490 40
TYR: tyrosinase Hs.2053 7299 38
MLPH: melanophilin Hs.297405 79083 7
MITF: microphthalmia-
associated transcription
factor
Hs.16607 4286 6
aSynonymous with ocular albinism type 1 protein.
bSynonymous with tyrosinase-related protein 2.
Table III. DM versus NDM: non-pigmentation genes differing at
least tenfold in expression
Gene name UniGene
Gene
ID
DM
versus
NDM (fold
change)
CLU: clusterin Hs.436647 1191 þ31
RARRES1: retinoic acid
receptor responder
Hs.82547 5918 þ25
FABP7: fatty acid binding
protein 7, brain
Hs.26770 2173 þ21
HLA-DQA1: major
histocompatibility complex,
class II, DQ alpha 1
Hs.387679 3117 þ16
IGFBP5: insulin-like growth
factor binding protein 5
Hs.512226 3488 þ15
TFPI2: tissue factor pathway
inhibitor 2
Hs.438231 7980 þ15
TPM2: tropomyosin 2 Hs.300772 7169 þ15
RRAD: Ras-related associated
with diabetes
Hs.1027 6236 þ14
TTID: Titin immunoglobulin
domain protein
Hs.84665 9499 þ14
PTN: pleiotrophin Hs.44 5761 þ14
COL11A1 collagen, type XI, a1 Hs.439168 1301 þ13
NGFR: nerve growth factor
receptor
Hs.415768 4804 þ13
C10orf81: chromosome 10
open reading frame 81
Hs.228320 79949 þ13
GFRA3: GDNF family receptor a3 Hs.58042 2676 þ12
TIMP4: tissue inhibitor of
metalloproteinase 4
Hs.190787 7079 þ11
SERPINA3: serine proteinase
inhibitor, clade A, member 3
Hs.76353 12 þ10
BCAN: brevican Hs.158515 63827 12
GTSTT1: glutathione
S-transferase y1
Hs.268573 2952 12
MBP: myelin basic protein Hs.408543 4155 14
MATP: membrane associated
transporter
Hs.278962 51151 15
PRAME: preferentially
expressed antigen in melanoma
Hs.30743 23532 15
MCF2L: MCF.2 cell line derived
transforming sequence-like
Hs.436905 23263 16
SOSTDC1: sclerostin domain
containing 1
Hs.25956 25928 16
CART1: cartilage paired-class
homeoprotein 1
Hs.41683 8092 17
GREB1: GREB1 protein Hs.438037 9687 17
KCNJ13: potassium inwardly-
rectifying channel, subfamily J,
member 13
Hs.467338 3769 19
SLC6A15: solute carrier family
6, member 15
Hs.44424 55117 98
DM, desmoplastic melanoma; NDM, non-desmoplastic melanoma.
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Jain and Allen described DMM as ‘‘collagenizing fibrosar-
coma-like tumors’’ (Smithers et al, 1990).
A number of studies have indicated a difference in the
clinical presentation and behavior of DM compared with
non-desmoplastic tumors (Conley et al, 1971; Egbert et al,
1988; Jain and Allen, 1989; Smithers et al, 1990; Baer et al,
1995; Carlson et al, 1995; Skelton et al, 1995; Quinn et al,
1998; Jaroswewski et al, 2001; Thelmo et al, 2001; Gyorki
et al, 2003). DM tend to affect elderly individuals with
chronically sun-damaged skin. Although they have a high
rate of local skin or subcutaneous recurrences, regional
lymph node involvement seems to be less common (Quinn
et al, 1998; Jaroswewski et al, 2001; Thelmo et al, 2001;
Gyorki et al, 2003).
The difference in morphologic appearance and clinical
behavior between tumors, such as between DM and NDM,
is assumed to reflect different patterns of genes expressed
in the respective tumor types. Accordingly, classification of
tumors by gene expression profiling should be feasible and
has been shown to be applicable for a number of neoplastic
systems resulting in validation and improvements of existing
histologic classification schemes (Staudt; Alizadeh et al,
2001; Segal et al, 2003). We have previously used gene
expression profiling to separate melanomas from sarcomas
(Segal et al, 2003). In this study, we sought to explore its
applicability to a limited set of DM and NDM. Our results
clearly indicate that gene expression profiling permits dis-
tinction of desmoplastic from non-desmoplastic variants of
primary cutaneous melanoma, thereby validating DM as a
distinct histologic subtype at the molecular level.
It is of interest that the one tumor with mixed desmo-
plastic and non-desmoplastic features showed overlap at
the genetic level as well. The case highlights the necessity
for strict definitions for the diagnosis of DM (Busam et al,
2004). If only tumors are accepted as DM, in which stromal
fibrosis is prominent throughout the entire invasive tumor
component, differences from NDM become more apparent.
Likewise, if cases with only partial tumor fibrosis are in-
cluded, differences may be less evident.
Aside from classification issues, i.e. whether gene ex-
pression profiling would support the histologic subclassifi-
cation of DM, we were interested in identifying genes
associated with DM or NDM. The results should confirm
known and might reveal new differences in gene expression
patterns, which would be helpful for hypotheses on the bi-
ology of the tumors and possibly be relevant for the devel-
opment of new diagnostic reagents.
Since the invasive component of DM is typically am-
elanotic, one would expect DM to differ from NDM in the
level of expression of genes involved in melanin pigment
synthesis or melanosomes (Table II). Indeed, the genes for
oculocutaneous albinism (G protein-coupled receptor 143)
(Shen and Orlow, 2001), DTC (Schiaffino et al, 1996; Guy-
onneau et al, 2004), which is also known as TRP-2, melan-
A/Mart-1 (Busam et al, 1998), tyrosinase (Jungbluth et al,
2000), gp100 (Busam et al, 2001), microphthalmia-associ-
ated transcription factor (MITF) (Busam et al, 2001), and
melanophilin (MLPHN) (Fikuda et al, 2002) were significantly
decreased in DM compared with NDM. Their downregula-
tion in DM corresponded well with results of immunohisto-
chemical studies for a subset of these markers (Table IV),
and is consistent with prior reports of the immunoprofile of
DM (Baer et al, 1995; Busam et al, 2001, 2004; Winnepen-
nickx et al, 2003). This type of melanoma is usually immuno-
negative for various melanocyte differentiation antigens
related to pigment synthesis (Baer et al, 1995; Busam et al,
2001, 2004; Winnepennickx et al, 2003). Since the non-
desmoplastic tumors of this series were pauci-melanotic,
the differences reported in Table II would likely be much
higher, if DM were compared with heavily pigmented
melanomas. Although all of the genes listed in Table II
have previously been shown to be present in melanoma
cells (Busam et al, 1998, 2001; Jungbluth et al, 2000),
immunohistochemical data comparing DM with NDM are
limited to melan-A/Mart-1, tyrosinase, gp100, and MITF
(Baer et al, 1995; Busam et al, 2001, 2004; Winnepennickx
et al, 2003). Antibodies to GP3143, DTC, or MLPH suitable
for staining archival tissue material are, to our knowledge,
not yet available.
DM differed from NDM in the expression of a number of
other genes not related to pigment synthesis. Table III lists
such genes with at least a 10-fold difference between DM
and NDM. They represent a diverse set of genes. Their ex-
pression (in tumor cells vs peritumoral stroma) and potential
role in the biology of melanoma will be the subject of future
studies. At this point, however, some findings already merit
comments.
Table IV. Immunohistochemical expression of melanocyte dif-
ferentiation antigens
1 2 3 4 5 6 7 8 9 10
S100 P 3þ 3þ 3þ 3þ 3þ 3þ 3þ 3þ 3þ 3þ
T311     3þ 3þ 3þ 3þ 3þ 3þ
A103     3þ 3þ 3þ 3þ 3þ 3þ
HMB-
45
     3þ 2þ 3þ 3þ 3þ
D5     2þ 3þ 3þ 3þ 3þ 3þ
Antibodies used: S100P, anti-S100 protein; T311, anti-tyrosinase;
A103, anti-Melan-A; HMB-45, anti-gp100; D5, anti-microphthalmia-as-
sociated transcription factor; 1–10, melanoma samples corresponding to
tumors from patients in Table I. Triplicate samples were analyzed from
different parts of the same invasive tumor; 3þ , positive immunostaining
of tumor cells in all triplicate samples; 2þ , positive immunostaining of
tumor cells in two of three samples; , no staining of tumor cells for the
respective marker in any of three samples.
TableV. Immunohistochemical expression of clusterin in tis-
sue microarrays of DM and NDM
Sample 1 2 3 4 5 6 7 8 9 10
A þ þ þ þ þ   þ  
B þ þ þ þ þ   þ  
C þ þ þ þ    þ  
Samples 1–4, DM; sample 5, CDM; samples 6–10, NDM; A–C, triplicate
tissues samples (1 mm in diameter) from different parts of the same
invasive tumor; þ , positive immunostaining of tumor cells; , no
immunostaining of tumor cells.
DM, desmoplastic melanoma; NDM, non-desmoplastic melanoma;
CDM, combined desmoplastic melanoma.
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It is apparent from Table III that several genes involved
in the production and homeostasis of extracellular matrix
(collagen as well as proteinase inhibitors, such as TFIP2,
TIMP4, SERPINA3) are more prominently expressed in DM
than NDM. This is to be expected and makes sense bio-
logically. A collagen-rich matrix is the histologic hallmark of
DM and prominent expression of various proteinase inhib-
itors should facilitate the accumulation of matrix proteins
(Bou Gharios et al, 1994). Expression of tissue metal-
loproteinase inhibitors by melanocytes has previously been
documented (Krengel et al, 2002). It is likely that some of
the upregulated genes, such as collagen, however, are ex-
pressed by peritumoral fibroblasts (Kubo et al, 1998).
DM frequently also shows morphologic and immuno-
histochemical evidence of neural or Schwannian differenti-
ation. It has, for example, previously been documented that
the NGFR is prominently expressed in DM (Kanik et al,
1996; Iwamoto et al, 2001). Our finding of an increased ex-
pression of NGFR in DM is in keeping with this observation.
Other neurotrophic genes, whose expression was more
then 10-fold increased in the DM of this series, included the
glial cell line-derived neurotrophic factor receptor family
(Blesch and Tuszynski, 2003) and pleiotrophin (heparin
binding growth factor 8, neurite growth promoting factor 1)
(Seykora et al, 2003; Kadomatsu and Muramatsu, 2004).
The protein of the latter gene is, as implied by its name,
involved in many diverse biologic processes (Kadomatsu
and Muramatsu, 2004).
An interesting and novel observation was the association
of clusterin with DM. Clusterin is an 80 kDa heterodimeric
gp that was first isolated from ram testis fluid (Blaschuk
et al, 1983; Jones and Jomary, 2002; Saffer et al, 2002;
Leskov et al, 2003; Pucci et al, 2004; Scaltriti et al, 2004). It
was given its name because its protein could induce clus-
tering of Sertoli cells. Clusterin is secreted in physiological
fluids and expressed in a variety of normal tissues and
tumors. It has been implicated in diverse physiological proc-
esses reflected in various names given to the same protein
(Jones and Jomary, 2002). Suggested functions include cell
adhesion and cell–extracellular matrix interaction, tissue re-
modeling, promotion as well as inhibition of apoptosis,
membrane lipid recycling, and a role as a stress-induced
secreted chaperone protein (Blaschuk et al, 1983; Jones and
Jomary, 2002; Saffer et al, 2002; Leskov et al, 2003; Pucci
et al, 2004; Scaltriti et al, 2004). No clear picture about the
significance of clusterin in tumor biology has emerged yet.
Its impact on cell growth or death may depend on the cell
type and the expressed isoform (Pucci et al, 2004). Although
more studies are needed to determine the significance of
clusterin for the biology of melanomas, it is of interest that
this protein has previously been linked to fibrogenic proc-
esses (Sadlier et al, 2004) and has been reported to be able
to function as a metalloproteinase inhibitor (Matsuda et al,
2003). It is therefore tempting to speculate that clusterin may
be involved in the generation of the fibrous stroma associ-
ated with DM.
Since among all genes found to be upregulated in DM,
the difference between DM and NDM was the greatest for
clusterin, we studied its expression by immunohistochem-
istry. The difference in gene expression was paralleled by
immunohistochemical findings, which showed that staining
for clusterin was present in tumor cells and more often
found in DM than NDM (Fig 3, Table V).
For the practicing pathologist, DM is of particular interest
as a tumor that may be difficult to recognize as melanoma
(Troxel, 2003). It may be confused with non-melanocytic
spindle cell proliferations, such as a fibroma or sarcoma
(Daimaru et al, 1985; King et al, 1999; Troxel, 2003). The
need for improved diagnostic accuracy of DM has led to
several studies exploring the potential use of various
Figure 3
Immunohistochemical expression of clusterin
(tissue microarray analysis). (A) Hematoxylin
and eosin (H&E)-stained section of desmoplastic
melanoma (DM). (B) DM is immunopositive for
clusterin. (C) H&E stain of non-desomplastic
melanoma (NDM). (D) NDM is immunonegative
for clusterin.
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immunomarkers. Little progress has been made in this
regard, however. As illustrated here (Table IV) and docu-
mented by several investigators before, DM is typically
negative for the majority of melanocyte differentiation
antigens. Antibodies to S-100 protein remain the most
useful reagents for the diagnosis of DM. Although S-100
protein is a sensitive marker for melanocytes, unfortu-
nately, it lacks specificity (Daimaru et al, 1985; King et al,
1999; Busam et al, 2001; Koch et al, 2001; Robson
et al, 2001).
Thus, there is a need for the development of markers or
methods more specific for DM. Gene expression profiling
has the potential to assist in this regard. If the pattern of
expressed genes of DM is compared with those of its clos-
est morphologic mimics (various types of sarcomas and
spindle cell sarcomatoid carcinomas), novel genes may be
identified for the diagnosis of DM. Furthermore, gene
expression profiling itself may be used for tumor diagnosis.
If fresh tissue of a tumor that is difficult to classify by con-
ventional (morphologic and immunohistochemical) means
is available, microarray analysis may allow its proper clas-
sification. We have previously demonstrated the utility of
molecular profiling in the distinction of melanomas from
sarcomas (Segal et al, 2003). Future studies will examine
the potential use of this technology for the specific distinc-
tion of DM from its mimics.
Although a larger number of tumors would have been
desirable for the study reported herein, this is difficult to
achieve for a number of reasons. DM is a rare variant of
melanoma constituting less than 1% of primary melanomas.
The vast majority of patients referred to a cancer center with
a diagnosis of melanoma already have their primary tumor
completely or near completely excised. Thus, the number of
patients with sufficient amounts of residual and reasonably
homogenous invasive tumor tissue that can be collected for
a tumor bank and used for analysis by the methodology
described herein is very small. The scarcity of suitable
tumor tissue is apparent by the fact that it took us 4 y to
collect the DM analyzed herein. This experience illustrates
the need for multicenter studies for significant progress to
be made in gene expression profiling of human melanoma
tissues unless technological advances are achieved in
adopting the methodology for much smaller tissue sam-
ples or ideally to archival material.
In conclusion, we have demonstrated in this study that
microarray data allow a clear separation of DM from NDM,
thereby validating an existing histologic subclassification of
melanoma borne out of traditional studies correlating his-
tomorphologic findings with clinical behavior. Although our
results confirm that DM differs markedly from NDM at the
level of expression of genes related to melanin pigment
synthesis, they also revealed a number of other genes of
potential interest for the classification of melanomas. Future
studies are needed to explore their relevance and associ-
ation with DM or NDM.
Materials and Methods
Tissue samples Samples were obtained from fresh skin excisions
of patients with melanoma according to guidelines of an Institu-
tional Review Board-approved protocol. All specimens were ex-
amined grossly and sectioned by a single dermatopathologist (K. J.
B.). The thickest part of a tumor was used for routine diagnosis to
document greatest depth of invasion. The tissue samples used for
this analysis were macroscopically apparent dermal and subcuta-
neous components of tumor near but not directly at the site of
greatest measured thickness. All grossly visible non-tumorous tis-
sue (overlying or adjacent skin and fragments of surrounding
adipose tissue) was removed. Even if the epidermis overlying a
melanoma contained tumor cells (in situ melanoma), it was none-
theless excluded from the tissue sample to minimize the presence
of non-neoplastic cells, such as epidermal keratinocytes, and to
assure that only invasive tumor was submitted for analysis. The
tumor tissue was frozen in liquid nitrogen and stored at 701C. A
thin section of the frozen sample was examined microscopically to
verify that lesional tissue was present and to judge the ‘‘purity’’ and
cellularity of the tumor (all frozen tissue samples contained at least
85% lesional, i.e. tumor cells per total cell population). Hematoxylin
and eosin (H&E)-stained sections of the entire excision with tumor,
including the section corresponding to the frozen tumor tissue
sample, were reviewed by a single dermatopathologist for meas-
urements of tumor thickness and histologic classification of the
tumor. For a tumor to be designated as DM, it had to be composed
of amelanotic spindle cells dispersed in a prominent fibrosing
stroma. The NDM selected for this series consisted of tumors
lacking significant associated fibrosis.
Immunohistochemistry Immunohistochemical studies were
performed with an avidin–biotin–peroxidase system (ABC, Vector
Laboratories, Burlington, California) using a biotinylated horse anti-
mouse secondary antibody (Vector Laboratories, 1:200). The pri-
mary antibodies used included anti-S100 protein (BioGenex, San
Ramon, California; 1:50,000), A103 (Dako, Carpinteria, California;
1:50), HMB-45 (Dako, 1:500), D5 (Neomarker, Fremont, California),
and T311 (Novocastra; 1:200, Novacostra, Norwell, Massachu-
setts), and clusterin (clone 41D, Upstate Biotech, Lake Placid, New
York, 1:100). The primary antibodies were diluted in commercially
available diluent (Protocol, Fisher Scientific, Middletown, Virginia).
3,300 Diamino-benzidine tetrahydrochloride (BioGenex) was used
as chromogen. Endogenous peroxidase was suppressed with 1%
H2O2 for 20 min. The slides were counterstained with hematoxylin
(Sigma, St Louis, Missouri). For antigen retrieval of all antibodies
except for S-100 protein, slides were heated in a buffer solution
using a vegetable steamer (931C, 30 min).
Tissue arrays Tissue microarrays (TMA) were assembled using a
Manual Tissue Arrayer I (Beecher Instruments, Sun Prairie, Wis-
consin). Three cylinders per tissue were arrayed using punch bi-
opsy needles with a diameter of 0.6 mm taken from formalin-fixed
and paraffin-embedded tissue blocks. Before taking the biopsies,
the tumor portion was examined on routine H&E-stained sections
and tumor cell-rich areas were marked and matched with the cor-
responding areas of the tissue block. Newly assembled TMA
blocks were heated to 601C for 5 min and the surface was leveled
with a glass slide. TMA sections were cut. Charged slides (Super-
frost, Fisher Scientific, Pittsburgh, Pennsylvania) were used and
after application of 5 mm cuts, heated for at least 2 h at 601C to
ensure proper attachment. H&E-stained sections of the array were
examined by light microscopy to assure that lesional (tumor tissue)
was present.
RNA extraction and processing for oligonucleotide array anal-
ysis Total RNA was extracted with Trizol (Invitrogen Life Technol-
ogies, Carlsbad, California) and quality control was performed prior
to labeling. Twenty-five to 50 nanograms of total RNA was run on
a RNA 6000 Nano Assay (Agilent, Palo Alto, California) using a
Bioanalyzer 2100 (Agilent, Palo Alto, California). Two micrograms of
good-quality total RNA was then labeled according to protocols
recommended by the manufacturers. Briefly, after reverse tran-
scription with an oligo-dT(24)-T7 (Genset), double-stranded cDNA
was generated with the superscript double-stranded cDNA
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synthesis custom kit (Invitrogen Life Technologies). In an in vitro
Transcription step (IVT) with T7 RNA polymerase (MessageAmp
aRNA kit from Ambion, Austin, Texas), the cDNA was linearly am-
plified and labeled with biotinylated nucleotides (Enzo Diagnostics,
Farmingdale, New York). Ten micrograms of labeled and fragment-
ed cRNA was then hybridized onto a Human genome U133A ex-
pression array (Affymetrix, Santa Clara, California) for 16 h at 451C.
Post-hybridization staining, washing were processed according to
the manufacturer (Affymetrix). Finally, chips were scanned with a
Hewlett Packard argon-ion laser confocal scanner. The image was
quantified using MAS 5.1 (MicroArray Suite, Affymetrix) with the
default parameters for the statistical algorithm and all probe set
scaling with a target intensity of 500.
Data analysis To eliminate variation because of samples prepa-
ration we performed a per chip normalization (by dividing all of the
measurements on each chip by the median), and a per gene nor-
malization to the median. We also filtered out genes that are absent
across all of the samples. We then identified genes differential-
ly expressed between DM and NDM samples using a parametric
test with filtering (p-values o0.05) on variances estimated by the
cross-gene error model (also known as the Rocke–Lorenzato
model). With the filtered gene list, hierarchical clustering was per-
formed, with similarity measured by standard correlation.
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